Rituximab in refractory sarcoidosis: a single centre experience

Case Report

Francesco Cinetto, Nicolò Compagno, Riccardo Scarpa, Giacomo Malipiero and Carlo Agostini^*

Clinical and Molecular Allergy 2015, 13:19  doi:10.1186/s12948-015-0025-9

Abstract

Sarcoidosis is a granulomatous disease whose outcome varies from spontaneous remission to chronic refractory disease. Provided that steroids represent the gold standard as a first line treatment, many immune suppressants drugs are currently used in the disease management. However, refractory disease is still a great challenge. Rituximab is an anti-CD20 chimeric monoclonal antibody, currently used for the treatment of B cell malignancies and systemic autoimmune diseases.

There are few case reports describing the successful use of Rituximab in refractory sarcoidosis with lung, eye, lymph nodes and skin involvement. In this paper we described three different case reports in which Rituximab has been used to treat refractory sarcoidosis and we reviewed the existing literature.

Keywords: 

Refractory sarcoidosis; Rituximab; Granulomatosis 

Viewing options

• Full text

• PDF (969KB)

• ePUB (34KB)